Inhibrx Biosciences Inc. (INBX)
NASDAQ: INBX
· Real-Time Price · USD
23.50
-0.44 (-1.84%)
At close: Aug 15, 2025, 10:04 AM
-1.84% (1D)
| Bid | 16.95 |
| Market Cap | 340.26M |
| Revenue (ttm) | 200K |
| Net Income (ttm) | 1.72B |
| EPS (ttm) | -16.57 |
| PE Ratio (ttm) | -1.42 |
| Forward PE | -2.29 |
| Analyst | n/a |
| Ask | 30.48 |
| Volume | 7,243 |
| Avg. Volume (20D) | 106,577 |
| Open | 23.98 |
| Previous Close | 23.94 |
| Day's Range | 23.38 - 24.19 |
| 52-Week Range | 10.80 - 25.29 |
| Beta | 0.22 |
About INBX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INBX
Website n/a
3 months ago
+10.89%
Inhibrx Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago · seekingalpha.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformINBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p...